Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biondvax Pharma ADR
(NQ:
BVXV
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biondvax Pharma ADR
< Previous
1
2
3
4
5
6
7
8
Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth
February 08, 2023
Via
Investor Brand Network
New Model Sheds Light on Patterns of Infectious Illnesses
February 07, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target
February 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
February 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
January 23, 2023
Via
Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
February 02, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Presenting at BIO CEO & Investor Conference
February 02, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Research Links Two Natural Deposits to Onset of Macular Degeneration
January 31, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
January 30, 2023
Via
Investor Brand Network
Exposures
COVID-19
Toddlers, Infants Risk Severe Outcomes When Faced with Multiple Infections
January 24, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
January 23, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
January 23, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
January 23, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 19, 2023
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.
Via
Benzinga
Scientists Discover Unknown T Cell Function That Can Help Fight Fungal Infections
January 17, 2023
Via
Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs
January 17, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
January 13, 2023
Via
Investor Brand Network
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Tuesday
January 10, 2023
Tuesday's session saw 16 companies set new 52-week lows.
Via
Benzinga
America Faces Shortage of Infectious Disease Experts
January 09, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
January 06, 2023
Via
Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus
January 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
January 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
January 06, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase
January 05, 2023
Via
Investor Brand Network
Exposures
COVID-19
BiondVax to Present at Biotech Showcase 2023
January 05, 2023
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements
January 04, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders
January 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Tuesday
January 03, 2023
On Tuesday, 31 stocks hit new 52-week lows.
Via
Benzinga
BiondVax CEO Issues Letter to Shareholders
December 30, 2022
From
BiondVax Pharmaceuticals Ltd.
Via
GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market
December 29, 2022
Via
Investor Brand Network
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
